Physician profile
George Samaan
NPI 1255794756
$6,482.52
in general payments reported to CMS, 2019-2025
14 companies · $510 in 2025
The $510 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $164 · 2022: $279 · 2023: $5,135 · 2024: $395 · 2025: $510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $4,000 · Food and Beverage: $1,875 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $4,000.00 |
| Food and Beverage | $1,875.07 |
| Education | $164.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,420.18 | 2023-2025 | Onyx Frontier, Corevalve Evolut R, Selectsecure |
| Abbott Laboratories | $532.75 | 2021-2023 | Supera, Merlin@Home, Assurity |
| Abiomed | $458.12 | 2022-2025 | Impella |
| Shockwave Medical, INC | $297.30 | 2024-2025 | Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Inari Medical, INC. | $197.07 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Astellas Pharma US INC | $136.57 | 2021 | |
| Angiodynamics, INC. | $133.08 | 2022 | |
| Novartis Pharmaceuticals Corporation | $88.93 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $83.63 | 2024-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.75 | 2024-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $38.98 | 2023-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $23.54 | 2024 | Farxiga |
| Boston Scientific Corporation | $16.02 | 2025 | General - Therapies |
| Microvention, INC. | $14.60 | 2023 | Eric Retrieval Device |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Samaan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.